𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Does Valganciclovir Hydrochloride (Valcyte) Provide Effective Prophylaxis Against Cytomegalovirus Infection in Liver Transplant Recipients?

✍ Scribed by A. Jain; M. Orloff; R. Kashyap; K. Lansing; R. Betts; R. Mohanka; M. Menegus; C. Ryan; A. Bozorgzadeh

Book ID
116931468
Publisher
Elsevier Science
Year
2005
Tongue
English
Weight
185 KB
Volume
37
Category
Article
ISSN
0041-1345

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Question of using valganciclovir for cyt
Question of using valganciclovir for cytomegalovirus (CMV) infection prophylaxis in post–liver transplant recipients
✍ Ashok Jain; Ravi Mohanka; Mark Orloff; Peter Abt; Charlotte Ryan; Adel Bozorgzad πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 46 KB

We read the article by Park et al. with great interest. 1 The authors retrospectively studied the efficacy of low-dose oral valganciclovir (n Ο­ 49) compared with the standard dose of ganciclovir (n Ο­ 60) for the prevention of cytomegalovirus (CMV) disease in adult liver transplant recipients. The au

Increased incidence of cytomegalovirus i
Increased incidence of cytomegalovirus infection in high-risk liver transplant recipients receiving valganciclovir prophylaxis versus ganciclovir prophylaxis
✍ Kevin T. Shiley; Leanne B. Gasink; Todd D. Barton; Patrice Pfeiffenberger; Kim M πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 83 KB πŸ‘ 1 views

Optimal measures for the prevention of cytomegalovirus (CMV) in high-risk orthotopic liver transplant (OLT) patients are unknown. The charts of high-risk OLT recipients with 12 months of follow-up who were transplanted over a 44-month period were reviewed. The incidence of CMV disease in CMV-seropos